546 related articles for article (PubMed ID: 34627490)
1. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.
Kim CJ; Park MW; Kim MC; Choo EH; Hwang BH; Lee KY; Choi YS; Kim HY; Yoo KD; Jeon DS; Shin ES; Jeong YH; Seung KB; Jeong MH; Yim HW; Ahn Y; Chang K;
Lancet; 2021 Oct; 398(10308):1305-1316. PubMed ID: 34627490
[TBL] [Abstract][Full Text] [Related]
2. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Holdt L; Felix SB; Parma R; Klopotowski M; Schwinger RHG; Rieber J; Huber K; Neumann FJ; Koltowski L; Mehilli J; Huczek Z; Massberg S;
Lancet; 2017 Oct; 390(10104):1747-1757. PubMed ID: 28855078
[TBL] [Abstract][Full Text] [Related]
3. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.
Kim HS; Kang J; Hwang D; Han JK; Yang HM; Kang HJ; Koo BK; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Park KW;
Lancet; 2020 Oct; 396(10257):1079-1089. PubMed ID: 32882163
[TBL] [Abstract][Full Text] [Related]
4. Dual Antiplatelet Therapy De-Escalation in Stabilized Myocardial Infarction With High Ischemic Risk: Post Hoc Analysis of the TALOS-AMI Randomized Clinical Trial.
Lee M; Byun S; Lim S; Choo EH; Lee KY; Moon D; Choi IJ; Hwang BH; Kim CJ; Park MW; Choi YS; Kim HY; Yoo KD; Jeon DS; Yim HW; Chang K;
JAMA Cardiol; 2024 Feb; 9(2):125-133. PubMed ID: 38117483
[TBL] [Abstract][Full Text] [Related]
5. Prognosis and the Effect of De-Escalation of Antiplatelet Therapy After Nuisance Bleeding in Patients With Myocardial Infarction.
Choo EH; Choi IJ; Lim S; Moon D; Kim CJ; Park MW; Kim MC; Hwang BH; Lee KY; Seok Choi Y; Kim HY; Yoo KD; Jeon DS; Ahn Y; Chang K;
Circ Cardiovasc Interv; 2022 Dec; 15(12):e012157. PubMed ID: 36382599
[TBL] [Abstract][Full Text] [Related]
6. A prospective, multicentre, randomised, open-label trial to compare the efficacy and safety of clopidogrel versus ticagrelor in stabilised patients with acute myocardial infarction after percutaneous coronary intervention: rationale and design of the TALOS-AMI trial.
Park MW; Kim CJ; Kim MC; Choo EH; Hwang BH; Park CS; Kim HY; Yoo KD; Jeon DS; Jeong MH; Seung KB; Ahn Y; Chang K
EuroIntervention; 2021 Feb; 16(14):1170-1176. PubMed ID: 32718912
[TBL] [Abstract][Full Text] [Related]
7. De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy.
Kim MC; Ahn SG; Cho KH; Sim DS; Hong YJ; Kim JH; Jeong MH; Lee JW; Youn YJ; Kim HY; Yoo KD; Jeon DS; Shin ES; Jeong YH; Chang K; Ahn Y
EuroIntervention; 2023 Dec; 19(10):e832-e843. PubMed ID: 37724337
[TBL] [Abstract][Full Text] [Related]
8. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
Hahn JY; Song YB; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Kim J; Choi KH; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Gwon HC;
Lancet; 2018 Mar; 391(10127):1274-1284. PubMed ID: 29544699
[TBL] [Abstract][Full Text] [Related]
9. A novel de-escalation antiplatelet therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Li Y; Lei M; Yang Y; An L; Zhou H; Wang J; Zhao Z; Wang X; Nie S; Wang X; Hau WK; Xue Z
Medicine (Baltimore); 2023 Jul; 102(27):e34153. PubMed ID: 37417626
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of dual antiplatelet de-escalation therapy on the prognosis of patients with ST segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Zhao Z; Wang J; Lei M; Li Y; Yang Y; An L; Sun X; Li C; Xue Z
BMC Cardiovasc Disord; 2023 Mar; 23(1):168. PubMed ID: 36991321
[TBL] [Abstract][Full Text] [Related]
11. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.
Vranckx P; Valgimigli M; Jüni P; Hamm C; Steg PG; Heg D; van Es GA; McFadden EP; Onuma Y; van Meijeren C; Chichareon P; Benit E; Möllmann H; Janssens L; Ferrario M; Moschovitis A; Zurakowski A; Dominici M; Van Geuns RJ; Huber K; Slagboom T; Serruys PW; Windecker S;
Lancet; 2018 Sep; 392(10151):940-949. PubMed ID: 30166073
[TBL] [Abstract][Full Text] [Related]
12. Switching from ticagrelor to clopidogrel in patients with ST-segment elevation myocardial infarction undergoing successful percutaneous coronary intervention in real-world China: Occurrences, reasons, and long-term clinical outcomes.
Li XY; Su GH; Wang GX; Hu HY; Fan CJ
Clin Cardiol; 2018 Nov; 41(11):1446-1454. PubMed ID: 30225843
[TBL] [Abstract][Full Text] [Related]
13. De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis.
De Filippo O; Piroli F; Bruno F; Bocchino PP; Saglietto A; Franchin L; Angelini F; Gallone G; Rizzello G; Ahmad M; Gasparini M; Chatterjee S; De Ferrari GM; D'Ascenzo F
BMJ Evid Based Med; 2024 May; 29(3):171-186. PubMed ID: 38242567
[TBL] [Abstract][Full Text] [Related]
14. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
[TBL] [Abstract][Full Text] [Related]
15. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
[TBL] [Abstract][Full Text] [Related]
16. DAPT de-escalation from ticagrelor to clopidogrel 1 mo after PCI for acute MI reduced net clinical events at 1 y.
Bach RG
Ann Intern Med; 2022 Mar; 175(3):JC27. PubMed ID: 35226532
[TBL] [Abstract][Full Text] [Related]
17. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
[TBL] [Abstract][Full Text] [Related]
18. Short-Term DAPT and DAPT De-Escalation Strategies for Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis.
Kuno T; Watanabe A; Shoji S; Fujisaki T; Ueyama H; Takagi H; Deharo P; Cuisset T; Bangalore S; Mehran R; Stone GW; Kohsaka S; Bhatt DL
Circ Cardiovasc Interv; 2023 Sep; 16(9):e013242. PubMed ID: 37609850
[TBL] [Abstract][Full Text] [Related]
19. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J
Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703
[TBL] [Abstract][Full Text] [Related]
20. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.
Koo BK; Kang J; Park KW; Rhee TM; Yang HM; Won KB; Rha SW; Bae JW; Lee NH; Hur SH; Yoon J; Park TH; Kim BS; Lim SW; Cho YH; Jeon DW; Kim SH; Han JK; Shin ES; Kim HS;
Lancet; 2021 Jun; 397(10293):2487-2496. PubMed ID: 34010616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
